JP2013512938A - ショ糖オクタ硫酸エステル亜鉛塩、それらの製造、ならびにその医薬品および化粧品用途 - Google Patents
ショ糖オクタ硫酸エステル亜鉛塩、それらの製造、ならびにその医薬品および化粧品用途 Download PDFInfo
- Publication number
- JP2013512938A JP2013512938A JP2012542475A JP2012542475A JP2013512938A JP 2013512938 A JP2013512938 A JP 2013512938A JP 2012542475 A JP2012542475 A JP 2012542475A JP 2012542475 A JP2012542475 A JP 2012542475A JP 2013512938 A JP2013512938 A JP 2013512938A
- Authority
- JP
- Japan
- Prior art keywords
- sucrose octasulfate
- salt
- compound
- zinc salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- -1 Sucrose octasulfate zinc salts Chemical class 0.000 title claims description 32
- 150000003751 zinc Chemical class 0.000 claims abstract description 18
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 51
- 239000011701 zinc Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 206010052428 Wound Diseases 0.000 claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- XISWAUUBQBEDFB-QRDGSJRXSA-F octapotassium;[(2r,3r,4s,5r,6r)-2-[(2s,3s,4r,5r)-3,4-disulfonatooxy-2,5-bis(sulfonatooxymethyl)oxolan-2-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate Chemical group [K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[O-]S(=O)(=O)O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](COS(=O)(=O)[O-])O[C@@]1(COS([O-])(=O)=O)O[C@@H]1[C@H](OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](COS([O-])(=O)=O)O1 XISWAUUBQBEDFB-QRDGSJRXSA-F 0.000 claims description 12
- 230000029663 wound healing Effects 0.000 claims description 12
- CPRSOZZDECJZKH-QRDGSJRXSA-F octasodium;[(2r,3r,4s,5r,6r)-2-[(2s,3s,4r,5r)-3,4-disulfonatooxy-2,5-bis(sulfonatooxymethyl)oxolan-2-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](COS(=O)(=O)[O-])O[C@@]1(COS([O-])(=O)=O)O[C@@H]1[C@H](OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](COS([O-])(=O)=O)O1 CPRSOZZDECJZKH-QRDGSJRXSA-F 0.000 claims description 11
- 230000035876 healing Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 231100000241 scar Toxicity 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 208000006934 radiodermatitis Diseases 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010012444 Dermatitis diaper Diseases 0.000 claims description 2
- 208000003105 Diaper Rash Diseases 0.000 claims description 2
- 208000010201 Exanthema Diseases 0.000 claims description 2
- 208000005230 Leg Ulcer Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 208000007287 cheilitis Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 201000005884 exanthem Diseases 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- 208000032544 Cicatrix Diseases 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 230000037387 scars Effects 0.000 claims 2
- 230000012292 cell migration Effects 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 8
- 150000002482 oligosaccharides Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000029774 keratinocyte migration Effects 0.000 description 7
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 0 *[C@]([C@@](C[N+]([O-])=O)O[C@@]1(CO)O[C@@]([C@]2*)OCC(CN=O)[C@@](*)C2[N+]([O-])=O)[C@]1[N+]([O-])=O Chemical compound *[C@]([C@@](C[N+]([O-])=O)O[C@@]1(CO)O[C@@]([C@]2*)OCC(CN=O)[C@@](*)C2[N+]([O-])=O)[C@]1[N+]([O-])=O 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241000532838 Platypus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940037201 oris Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 2
- 229960004291 sucralfate Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 2
- 229940007718 zinc hydroxide Drugs 0.000 description 2
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000010393 epithelial cell migration Effects 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000008215 regulation of wound healing Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0958689 | 2009-12-07 | ||
| FR0958689A FR2953522B1 (fr) | 2009-12-07 | 2009-12-07 | Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques |
| PCT/EP2010/068873 WO2011069921A1 (fr) | 2009-12-07 | 2010-12-03 | Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013512938A true JP2013512938A (ja) | 2013-04-18 |
| JP2013512938A5 JP2013512938A5 (cg-RX-API-DMAC7.html) | 2014-01-23 |
Family
ID=42044412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542475A Pending JP2013512938A (ja) | 2009-12-07 | 2010-12-03 | ショ糖オクタ硫酸エステル亜鉛塩、それらの製造、ならびにその医薬品および化粧品用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120245120A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2509989A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013512938A (cg-RX-API-DMAC7.html) |
| AR (1) | AR079312A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2953522B1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201127388A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011069921A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2977798B1 (fr) * | 2011-07-13 | 2016-07-29 | Urgo Lab | Utilisation de composes oligosaccharidiques pour la prevention et le traitement des cicatrices pathologiques |
| FR2977797B1 (fr) * | 2011-07-13 | 2014-01-17 | Urgo Lab | Utilisation cosmetique et/ou dermatologique de composes oligosaccharidiques pour la prevention et le traitement des vergetures |
| EP2793845A4 (en) * | 2011-12-21 | 2016-02-24 | Colgate Palmolive Co | METHOD AND PRODUCTS FOR DIAGNOSIS AND TREATMENT OF OVERHEATING |
| FR2991876B1 (fr) | 2012-06-13 | 2014-11-21 | Vivacy Lab | Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate |
| FR2993182B1 (fr) | 2012-07-13 | 2014-10-17 | Urgo Lab | Pansement a liberation prolongee d'actifs |
| CN103193835B (zh) * | 2013-04-18 | 2015-06-24 | 安徽赛诺制药有限公司 | 一种蔗糖八磺酸酯钠合成及纯化的方法 |
| CN114436858A (zh) * | 2020-11-03 | 2022-05-06 | 江苏开元药业有限公司 | 一种药用辅料的三乙胺盐的制备方法 |
| CN116063360A (zh) * | 2022-09-22 | 2023-05-05 | 麦吉丽生物科技有限公司 | 用于改善皮肤功能的二糖聚硫酸盐及其制备方法和用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62190127A (ja) * | 1985-12-24 | 1987-08-20 | マリオン・ラボラトリ−ズ・インコ−ポレ−テツド | 傷の治癒を促進するための合成多硫酸化オリゴ糖含有組成物 |
| JPH04506656A (ja) * | 1989-04-20 | 1992-11-19 | ブーク メディテック エイ／エス | 美容用組成物 |
| EP0640346A1 (en) * | 1987-12-21 | 1995-03-01 | BM Research A/S | Uses of sulphated sugars against inflammation |
| US5908836A (en) * | 1987-12-21 | 1999-06-01 | Bar-Shalom; Daniel | Protecting skin from radiation damage using sulphated sugars |
| WO2006017752A2 (en) * | 2004-08-05 | 2006-02-16 | Ivax Corporation | Sulfated oligosaccharides |
| WO2008149035A2 (fr) * | 2007-05-25 | 2008-12-11 | Laboratoires Urgo | Nouveau principe actif dans la cicatrisation et son utilisation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1390007A (fr) | 1964-04-13 | 1965-02-19 | Plage permettant d'intégrer sur un disque un enregistrement publicitaire ou autre | |
| AU607690B2 (en) | 1985-12-24 | 1991-03-14 | Marion Laboratories, Inc. | Use of synthetic sulfated saccharides to enhance wound healing |
| US5618798A (en) * | 1989-04-20 | 1997-04-08 | Bar-Shalom; Daniel | Use of sucralfate to treat baldness |
| FR2646604B1 (fr) | 1989-05-03 | 1994-02-04 | Fabre Medicament Pierre | Composition pour usage externe a base de sucralfate et son procede de preparation |
| DK86492D0 (da) | 1992-06-30 | 1992-06-30 | Bukh Meditec | Laegemiddel |
-
2009
- 2009-12-07 FR FR0958689A patent/FR2953522B1/fr not_active Expired - Fee Related
-
2010
- 2010-12-03 US US13/514,121 patent/US20120245120A1/en not_active Abandoned
- 2010-12-03 WO PCT/EP2010/068873 patent/WO2011069921A1/fr not_active Ceased
- 2010-12-03 EP EP10795975A patent/EP2509989A1/fr not_active Withdrawn
- 2010-12-03 JP JP2012542475A patent/JP2013512938A/ja active Pending
- 2010-12-06 TW TW099142344A patent/TW201127388A/zh unknown
- 2010-12-07 AR ARP100104511A patent/AR079312A1/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62190127A (ja) * | 1985-12-24 | 1987-08-20 | マリオン・ラボラトリ−ズ・インコ−ポレ−テツド | 傷の治癒を促進するための合成多硫酸化オリゴ糖含有組成物 |
| EP0640346A1 (en) * | 1987-12-21 | 1995-03-01 | BM Research A/S | Uses of sulphated sugars against inflammation |
| US5908836A (en) * | 1987-12-21 | 1999-06-01 | Bar-Shalom; Daniel | Protecting skin from radiation damage using sulphated sugars |
| JPH04506656A (ja) * | 1989-04-20 | 1992-11-19 | ブーク メディテック エイ／エス | 美容用組成物 |
| WO2006017752A2 (en) * | 2004-08-05 | 2006-02-16 | Ivax Corporation | Sulfated oligosaccharides |
| WO2008149035A2 (fr) * | 2007-05-25 | 2008-12-11 | Laboratoires Urgo | Nouveau principe actif dans la cicatrisation et son utilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2953522B1 (fr) | 2012-03-09 |
| US20120245120A1 (en) | 2012-09-27 |
| AR079312A1 (es) | 2012-01-18 |
| WO2011069921A1 (fr) | 2011-06-16 |
| WO2011069921A9 (fr) | 2011-09-15 |
| FR2953522A1 (fr) | 2011-06-10 |
| EP2509989A1 (fr) | 2012-10-17 |
| TW201127388A (en) | 2011-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512938A (ja) | ショ糖オクタ硫酸エステル亜鉛塩、それらの製造、ならびにその医薬品および化粧品用途 | |
| EP2498772B1 (en) | Composition and methods for improving skin appearance | |
| KR101669528B1 (ko) | 헤파란 술페이트의 정제 방법 및 미용학적 및 피부학적 제제에서 그의 용도 | |
| WO2007028256A2 (en) | Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation | |
| JP2014159488A5 (cg-RX-API-DMAC7.html) | ||
| KR102599755B1 (ko) | 동백 유래 플라보노이드를 포함하는 안티에이징 조성물 | |
| US10532018B2 (en) | Method of whitening skin using tranexamic acid-peptide having skin whitening activity | |
| FR3026011A1 (fr) | Composition contenant au moins un inhibiteur de certaines chimiokines, son procede d'obtention et son utilisation dermocosmetique pharmaceutique | |
| EP2935199B1 (en) | Esters of glycyrrhetinic acid, preparation and cosmetic applications thereof | |
| CN114376932B (zh) | 一种用于改善γ-氨基丁酸刺激性的组合物及其制备方法和应用 | |
| JP6272814B2 (ja) | ヒアルロン酸産生促進剤 | |
| IL262602A (en) | Amid derivatives of polycapoquinic acids, process for their preparation and uses | |
| CN113388044B (zh) | 一种蜗牛糖胺聚糖化合物、其药学上可接受的盐、制备方法及应用 | |
| JP5998211B2 (ja) | マグネシウムのスクロースオクタ硫酸エステル、その製造方法およびその医薬的および美容的使用 | |
| KR102074859B1 (ko) | 풀루란-레티노이드 접합체를 유효성분으로 포함하는 피부노화 방지용 조성물 | |
| EP2714706A1 (fr) | Sucroses octasulfates de calcium, leur préparation et leurs applications pharmaceutiques et cosmétiques | |
| JP7787552B2 (ja) | コラーゲン産生促進剤、細胞増殖促進剤及びシワ改善剤 | |
| JPH1017462A (ja) | メラニン生成抑制剤および美白化粧料 | |
| WO2024141003A1 (zh) | 一种透明质酸衍生物及其制备方法与应用 | |
| EP3052475B1 (en) | Pharmaceutical use of 3-benzylsulfonylpropionitrile | |
| KR20240147890A (ko) | 아시아틱애씨드와 n-아세틸-d-글루코사민의 합성화합물을 포함하는 피부 주름 개선용 화장료 조성물 | |
| KR102503111B1 (ko) | 트라첼로사이드를 포함하는 피부상태 개선용 조성물 | |
| KR102503106B1 (ko) | 테누이폴린을 포함하는 피부상태 개선용 조성물 | |
| KR20090105875A (ko) | 화장 조성물 내 활성제로서의, 노화 방지 특성을 갖는 알킬 글리코시드 또는 알킬 글리코시드의 혼합물의 용도, 및 상기 조성물을 사용하는 화장 케어 방법 | |
| JP2007509912A (ja) | オリゴラムノシドの直接合成法、オリゴラムノシド含有組成物および医薬としてのその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131202 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131202 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150320 |